Status:
COMPLETED
Ultra Rapid GEnome Sequencing
Lead Sponsor:
CMC Ambroise Paré
Conditions:
Whole Genome Sequencing
Eligibility:
All Genders
18+ years
Brief Summary
Next-generation sequencing (NGS) has revolutionized the field of genomics, allowing the detection of genetic abnormalities for diagnostic or therapeutic purposes. Turnaround times for exome or genome ...
Detailed Description
* Blood sample (5 ml) * Extraction of genomic DNA from lymphocytes * Ultra-rapid genome sequencing (48 hours for a whole genome), using the PromethION P2 Solo sequencer (Oxford Nanopore Technologies) ...
Eligibility Criteria
Inclusion
- No known progressive or chronic diseases
- Consent for participation
- Affiliation to a social security system
Exclusion
- Unable to understand
- Pregnant or breastfeeding women
- Subject under protection of the adults (guardianship, curators or safeguard of justice)
Key Trial Info
Start Date :
October 8 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 12 2024
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT06555731
Start Date
October 8 2024
End Date
October 12 2024
Last Update
December 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Rafaël
Levallois-Perret, Île-de-France Region, France, 92300